Generated by AI
Molecular Partners AG ADR is a clinical-stage biopharmaceutical company focused on designing and developing DARPin therapeutics, a proprietary protein-based platform used to create highly specific medicines. The company’s current work centers on therapies for oncology, immuno-oncology, ophthalmology, and other serious diseases, with programs spanning preclinical research and clinical trials. Its pipeline includes candidates designed to address solid tumors, blood cancers, retinal disorders, and other conditions where targeted protein engineering may offer therapeutic value. Molecular Partners AG ADR plays a specialized role in the biotechnology market by advancing novel biologic drug candidates and platform technologies for potential use in precision medicine. Headquartered in Schlieren, Switzerland, the company operates as a research-driven developer of innovative protein therapies for global healthcare applications.
WebsiteWagistrasse 14
Schlieren, 8952
Switzerland
The latest articles about MOLN.
Summary of Aug 25's posts. Generated by AI.
No summary yet.
No summary yet.
Detailed price information for Molecular Partners Ag ADR (MOLN-Q) from The Globe and Mail including charting and trades.
Summary of Apr 26's posts. Generated by AI.
Summary of Jun 18's posts. Generated by AI.
Investors talking about MOLN also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.